albireo
recognizes
pfic
awareness
day
boston
globe
newswire
albireo
pharma
nasdaq
albo
orphan
pediatric
liver
disease
company
developing
novel
bile
acid
modulators
joins
pfic
advocacy
resource
network
pfic
network
recognition
pfic
awareness
day
global
effort
support
patients
families
affected
progressive
familial
intrahepatic
cholestasis
pfic
pfic
rare
genetic
disorder
causes
progressive
liver
disease
characterized
intense
form
itching
called
pruritus
jaundice
difficulties
gaining
weight
maintaining
proper
nourishment
pfic
awareness
day
one
many
efforts
pfic
network
undertaking
lift
research
educational
advocacy
needs
devasting
disease
said
emily
ventura
executive
director
pfic
network
grateful
global
community
support
people
pfic
families
pfic
awareness
day
every
day
appreciate
research
commitment
companies
like
established
pfic
awareness
day
aims
highlight
impact
disease
patients
families
call
new
levels
support
including
research
advocacy
education
opportunities
connect
share
information
year
members
pfic
community
countries
around
world
come
together
virtually
using
hashtag
itchingforacure
social
media
pfic
network
also
offering
additional
ways
support
families
including
pfic
network
lemonade
stand
fundraiser
itchingforacure
campaign
apparel
purchase
patients
families
north
star
aligned
mission
providing
hope
families
continuing
advance
research
new
drug
treatment
option
pfic
said
ron
cooper
president
chief
executive
officer
albireo
pfic
awareness
day
opportunity
us
shine
light
patient
voices
salute
strength
perseverance
show
fight
recognize
pfic
awareness
day
albireo
supporting
itchingforacure
social
media
campaign
highlighting
pfic
families
around
world
including
messages
families
united
states
canada
united
kingdom
australia
company
also
continues
share
patient
perspectives
impact
pfic
online
platform
information
support
pfic
pfic
rare
genetic
disorder
causes
progressive
liver
disease
people
diagnosed
pfic
impaired
bile
flow
cholestasis
caused
genetic
mutations
resulting
bile
liver
cells
causes
liver
disease
symptoms
prominent
problematic
ongoing
manifestation
disease
pruritus
intense
itching
often
results
severely
diminished
quality
life
pfic
also
characterized
jaundice
poor
weight
gain
growth
many
cases
pfic
leads
cirrhosis
liver
failure
within
first
years
life
nearly
people
pfic
require
treatment
age
drugs
currently
approved
pfic
surgical
options
including
procedure
known
partial
external
biliary
diversion
pebd
liver
transplantation
options
carry
substantial
risks
additional
information
pfic
available
albireo
albireo
pharma
biopharmaceutical
company
focused
development
novel
bile
acid
modulators
treat
orphan
pediatric
liver
diseases
adult
liver
diseases
disorders
albireo
lead
product
candidate
odevixibat
developed
treat
rare
pediatric
cholestatic
liver
diseases
potential
become
first
approved
drug
treatment
patients
pfic
albireo
recently
reported
positive
results
pedfic
global
phase
clinical
trial
evaluating
efficacy
safety
odevixibat
first
largest
study
ever
conducted
company
intends
complete
regulatory
filings
eu
later
early
anticipation
potential
regulatory
approval
issuance
rare
pediatric
disease
priority
review
voucher
launch
second
half
company
also
plans
initiate
pivotal
phase
trial
odevixibat
alagille
syndrome
end
continues
enrolling
patients
bold
pivotal
phase
trial
odevixibat
biliary
atresia
information
albireo
please
visit
statements
press
release
includes
statements
within
meaning
private
securities
litigation
reform
act
statements
include
statements
statements
historical
fact
regarding
among
things
plans
progress
scope
cost
initiation
duration
enrollment
results
timing
availability
results
development
odevixibat
albireo
product
candidate
program
including
regarding
expectations
regarding
impact
business
ability
adapt
approach
appropriate
phase
clinical
program
odevixibat
patients
pfic
pivotal
trial
odevixibat
biliary
atresia
bold
planned
pivotal
trial
odevixibat
alagille
syndrome
target
indication
development
approval
size
design
population
location
conduct
cost
objective
enrollment
duration
endpoints
clinical
trial
timing
initiation
completion
availability
reporting
results
clinical
trial
including
extension
study
odevixibat
pfic
pivotal
trial
odevixibat
biliary
atresia
planned
pivotal
trial
odevixibat
alagille
syndrome
potential
approval
commercialization
odevixibat
discussions
fda
ema
regarding
programs
potential
benefits
competitive
position
odevixibat
elobixibat
albireo
product
candidate
program
commercial
opportunity
target
indication
potential
effects
odevixibat
treatment
pfic
patients
potential
improve
current
standard
care
potential
benefits
orphan
drug
designation
potential
issuance
rare
pediatric
disease
priority
review
voucher
period
albireo
cash
resources
sufficient
fund
operating
requirements
runway
albireo
plans
expectations
future
operations
financial
position
revenues
costs
expenses
albireo
often
uses
words
anticipates
believes
plans
expects
projects
future
intends
may
could
estimates
predicts
potential
planned
continue
guidance
similar
expressions
identify
statements
actual
results
performance
experience
may
differ
materially
expressed
implied
statement
result
various
risks
uncertainties
factors
including
limited
negative
impacts
pandemic
including
manufacturing
supply
conduct
initiation
clinical
trials
aspects
business
whether
favorable
findings
clinical
trials
odevixibat
date
including
findings
indications
pfic
predictive
results
clinical
trials
odevixibat
whether
either
fda
ema
determine
primary
endpoint
respective
evaluations
treatment
duration
phase
trial
patients
pfic
sufficient
support
approval
odevixibat
united
states
european
union
treat
pfic
symptom
pfic
specific
pfic
subtype
otherwise
outcome
interpretation
regulatory
authorities
ongoing
study
pooling
analyzing
pfic
patient
data
timing
initiation
completion
availability
data
clinical
trials
odevixibat
including
pivotal
program
biliary
atresia
planned
pivotal
program
alagille
syndrome
outcomes
trials
albireo
ability
obtain
coverage
pricing
reimbursement
approved
products
united
states
european
union
delays
challenges
recruitment
patients
conduct
phase
trial
pivotal
trials
albireo
critical
accounting
policies
risks
uncertainties
albireo
faces
described
greater
detail
heading
risk
factors
albireo
recent
annual
report
form
subsequent
filings
makes
securities
exchange
commission
result
risks
uncertainties
albireo
faces
results
events
indicated
statement
may
occur
albireo
cautions
place
undue
reliance
statement
addition
statement
press
release
represents
albireo
views
date
press
release
relied
upon
representing
views
subsequent
date
albireo
disclaims
obligation
update
statement
except
required
applicable
law
media
contact
colleen
alabiso
investor
contact
hans
vitzthum
lifesci
advisors
